This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Sancuso-product-image

SANCUSO®

SANCUSO transdermal patch is indicated for the prevention of nausea and vomiting associated with moderately or highly emetogenic multi-day chemotherapy in adult patients with swallowing difficulties.1

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

Prescribing information and adverse event reporting

Average:

  • References

    1. SANCUSO 3.1 mg/24 hours transdermal patch SPC.

    KKI/UK/IM-M1/0001 November 2023